(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...

Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage ...

The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomized, phase 3 trial. Lancet ...

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...

Dr. Alexander Decruyenaere presented the poster Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Dr.

Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September 17 th and 21 st was host to the session Mini oral session: GU tumours, ...